clinical trial · NCT05160922
Crizotinib Continuation Clinical Study
Pfizer·phase4·active not recruiting·n = 27
NSCLCALCLIMTcrizotinib
brief summary
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
started
Dec 27, 2021
primary completion
Mar 21, 2028
completion
Mar 21, 2028
last updated
Mar 30, 2026
detailed description
Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.
official title
CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol